Cargando…

Congenital hyperinsulinism: current trends in diagnosis and therapy

Congenital hyperinsulinism (HI) is an inappropriate insulin secretion by the pancreatic β-cells secondary to various genetic disorders. The incidence is estimated at 1/50, 000 live births, but it may be as high as 1/2, 500 in countries with substantial consanguinity. Recurrent episodes of hyperinsul...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnoux, Jean-Baptiste, Verkarre, Virginie, Saint-Martin, Cécile, Montravers, Françoise, Brassier, Anaïs, Valayannopoulos, Vassili, Brunelle, Francis, Fournet, Jean-Christophe, Robert, Jean-Jacques, Aigrain, Yves, Bellanné-Chantelot, Christine, de Lonlay, Pascale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199232/
https://www.ncbi.nlm.nih.gov/pubmed/21967988
http://dx.doi.org/10.1186/1750-1172-6-63
_version_ 1782214545101553664
author Arnoux, Jean-Baptiste
Verkarre, Virginie
Saint-Martin, Cécile
Montravers, Françoise
Brassier, Anaïs
Valayannopoulos, Vassili
Brunelle, Francis
Fournet, Jean-Christophe
Robert, Jean-Jacques
Aigrain, Yves
Bellanné-Chantelot, Christine
de Lonlay, Pascale
author_facet Arnoux, Jean-Baptiste
Verkarre, Virginie
Saint-Martin, Cécile
Montravers, Françoise
Brassier, Anaïs
Valayannopoulos, Vassili
Brunelle, Francis
Fournet, Jean-Christophe
Robert, Jean-Jacques
Aigrain, Yves
Bellanné-Chantelot, Christine
de Lonlay, Pascale
author_sort Arnoux, Jean-Baptiste
collection PubMed
description Congenital hyperinsulinism (HI) is an inappropriate insulin secretion by the pancreatic β-cells secondary to various genetic disorders. The incidence is estimated at 1/50, 000 live births, but it may be as high as 1/2, 500 in countries with substantial consanguinity. Recurrent episodes of hyperinsulinemic hypoglycemia may expose to high risk of brain damage. Hypoglycemias are diagnosed because of seizures, a faint, or any other neurological symptom, in the neonatal period or later, usually within the first two years of life. After the neonatal period, the patient can present the typical clinical features of a hypoglycemia: pallor, sweat and tachycardia. HI is a heterogeneous disorder with two main clinically indistinguishable histopathological lesions: diffuse and focal. Atypical lesions are under characterization. Recessive ABCC8 mutations (encoding SUR1, subunit of a potassium channel) and, more rarely, recessive KCNJ11 (encoding Kir6.2, subunit of the same potassium channel) mutations, are responsible for most severe diazoxide-unresponsive HI. Focal HI, also diazoxide-unresponsive, is due to the combination of a paternally-inherited ABCC8 or KCNJ11 mutation and a paternal isodisomy of the 11p15 region, which is specific to the islets cells within the focal lesion. Genetics and (18)F-fluoro-L-DOPA positron emission tomography (PET) help to diagnose diffuse or focal forms of HI. Hypoglycemias must be rapidly and intensively treated to prevent severe and irreversible brain damage. This includes a glucose load and/or a glucagon injection, at the time of hypoglycemia, to correct it. Then a treatment to prevent the recurrence of hypoglycemia must be set, which may include frequent and glucose-enriched feeding, diazoxide and octreotide. When medical and dietary therapies are ineffective, or when a focal HI is suspected, surgical treatment is required. Focal HI may be definitively cured when the partial pancreatectomy removes the whole lesion. By contrast, the long-term outcome of diffuse HI after subtotal pancreatectomy is characterized by a high risk of diabetes, but the time of its onset is hardly predictable.
format Online
Article
Text
id pubmed-3199232
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31992322011-10-24 Congenital hyperinsulinism: current trends in diagnosis and therapy Arnoux, Jean-Baptiste Verkarre, Virginie Saint-Martin, Cécile Montravers, Françoise Brassier, Anaïs Valayannopoulos, Vassili Brunelle, Francis Fournet, Jean-Christophe Robert, Jean-Jacques Aigrain, Yves Bellanné-Chantelot, Christine de Lonlay, Pascale Orphanet J Rare Dis Review Congenital hyperinsulinism (HI) is an inappropriate insulin secretion by the pancreatic β-cells secondary to various genetic disorders. The incidence is estimated at 1/50, 000 live births, but it may be as high as 1/2, 500 in countries with substantial consanguinity. Recurrent episodes of hyperinsulinemic hypoglycemia may expose to high risk of brain damage. Hypoglycemias are diagnosed because of seizures, a faint, or any other neurological symptom, in the neonatal period or later, usually within the first two years of life. After the neonatal period, the patient can present the typical clinical features of a hypoglycemia: pallor, sweat and tachycardia. HI is a heterogeneous disorder with two main clinically indistinguishable histopathological lesions: diffuse and focal. Atypical lesions are under characterization. Recessive ABCC8 mutations (encoding SUR1, subunit of a potassium channel) and, more rarely, recessive KCNJ11 (encoding Kir6.2, subunit of the same potassium channel) mutations, are responsible for most severe diazoxide-unresponsive HI. Focal HI, also diazoxide-unresponsive, is due to the combination of a paternally-inherited ABCC8 or KCNJ11 mutation and a paternal isodisomy of the 11p15 region, which is specific to the islets cells within the focal lesion. Genetics and (18)F-fluoro-L-DOPA positron emission tomography (PET) help to diagnose diffuse or focal forms of HI. Hypoglycemias must be rapidly and intensively treated to prevent severe and irreversible brain damage. This includes a glucose load and/or a glucagon injection, at the time of hypoglycemia, to correct it. Then a treatment to prevent the recurrence of hypoglycemia must be set, which may include frequent and glucose-enriched feeding, diazoxide and octreotide. When medical and dietary therapies are ineffective, or when a focal HI is suspected, surgical treatment is required. Focal HI may be definitively cured when the partial pancreatectomy removes the whole lesion. By contrast, the long-term outcome of diffuse HI after subtotal pancreatectomy is characterized by a high risk of diabetes, but the time of its onset is hardly predictable. BioMed Central 2011-10-03 /pmc/articles/PMC3199232/ /pubmed/21967988 http://dx.doi.org/10.1186/1750-1172-6-63 Text en Copyright ©2011 Arnoux et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Arnoux, Jean-Baptiste
Verkarre, Virginie
Saint-Martin, Cécile
Montravers, Françoise
Brassier, Anaïs
Valayannopoulos, Vassili
Brunelle, Francis
Fournet, Jean-Christophe
Robert, Jean-Jacques
Aigrain, Yves
Bellanné-Chantelot, Christine
de Lonlay, Pascale
Congenital hyperinsulinism: current trends in diagnosis and therapy
title Congenital hyperinsulinism: current trends in diagnosis and therapy
title_full Congenital hyperinsulinism: current trends in diagnosis and therapy
title_fullStr Congenital hyperinsulinism: current trends in diagnosis and therapy
title_full_unstemmed Congenital hyperinsulinism: current trends in diagnosis and therapy
title_short Congenital hyperinsulinism: current trends in diagnosis and therapy
title_sort congenital hyperinsulinism: current trends in diagnosis and therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199232/
https://www.ncbi.nlm.nih.gov/pubmed/21967988
http://dx.doi.org/10.1186/1750-1172-6-63
work_keys_str_mv AT arnouxjeanbaptiste congenitalhyperinsulinismcurrenttrendsindiagnosisandtherapy
AT verkarrevirginie congenitalhyperinsulinismcurrenttrendsindiagnosisandtherapy
AT saintmartincecile congenitalhyperinsulinismcurrenttrendsindiagnosisandtherapy
AT montraversfrancoise congenitalhyperinsulinismcurrenttrendsindiagnosisandtherapy
AT brassieranais congenitalhyperinsulinismcurrenttrendsindiagnosisandtherapy
AT valayannopoulosvassili congenitalhyperinsulinismcurrenttrendsindiagnosisandtherapy
AT brunellefrancis congenitalhyperinsulinismcurrenttrendsindiagnosisandtherapy
AT fournetjeanchristophe congenitalhyperinsulinismcurrenttrendsindiagnosisandtherapy
AT robertjeanjacques congenitalhyperinsulinismcurrenttrendsindiagnosisandtherapy
AT aigrainyves congenitalhyperinsulinismcurrenttrendsindiagnosisandtherapy
AT bellannechantelotchristine congenitalhyperinsulinismcurrenttrendsindiagnosisandtherapy
AT delonlaypascale congenitalhyperinsulinismcurrenttrendsindiagnosisandtherapy